US20200360289A1 - Freeze-dried product and gas-filled microvesicles suspension - Google Patents

Freeze-dried product and gas-filled microvesicles suspension Download PDF

Info

Publication number
US20200360289A1
US20200360289A1 US16/788,083 US202016788083A US2020360289A1 US 20200360289 A1 US20200360289 A1 US 20200360289A1 US 202016788083 A US202016788083 A US 202016788083A US 2020360289 A1 US2020360289 A1 US 2020360289A1
Authority
US
United States
Prior art keywords
freeze
microvesicles
gas
suspension
dried product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/788,083
Other languages
English (en)
Inventor
Michel Schneider
Eric ALLÉMANN
Philippe Bussat
Christian Guillot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bracco Suisse SA
Original Assignee
Bracco Suisse SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/688,540 external-priority patent/US20200360540A1/en
Application filed by Bracco Suisse SA filed Critical Bracco Suisse SA
Priority to US16/788,083 priority Critical patent/US20200360289A1/en
Priority to EP20726106.6A priority patent/EP3969065A1/fr
Priority to AU2020276679A priority patent/AU2020276679A1/en
Priority to KR1020217037356A priority patent/KR102626600B1/ko
Priority to SG11202111756UA priority patent/SG11202111756UA/en
Priority to KR1020217037784A priority patent/KR102624471B1/ko
Priority to KR1020247001478A priority patent/KR20240010559A/ko
Priority to CN202080035588.8A priority patent/CN113825529B/zh
Priority to PCT/EP2020/063559 priority patent/WO2020229642A1/fr
Priority to SG11202111754PA priority patent/SG11202111754PA/en
Priority to CN202080035142.5A priority patent/CN113811335A/zh
Priority to US17/610,853 priority patent/US11717570B2/en
Priority to US17/611,034 priority patent/US11426352B2/en
Priority to JP2021567832A priority patent/JP7357078B2/ja
Priority to CA3137089A priority patent/CA3137089A1/fr
Priority to PCT/EP2020/063560 priority patent/WO2020229643A1/fr
Priority to BR112021021791A priority patent/BR112021021791A2/pt
Priority to AU2020274620A priority patent/AU2020274620A1/en
Priority to CA3137088A priority patent/CA3137088C/fr
Priority to ES20726105T priority patent/ES2965028T3/es
Priority to JP2021567831A priority patent/JP7148742B2/ja
Priority to EP20726105.8A priority patent/EP3969064B1/fr
Priority to BR112021022185A priority patent/BR112021022185A2/pt
Publication of US20200360289A1 publication Critical patent/US20200360289A1/en
Priority to ZA2021/08052A priority patent/ZA202108052B/en
Priority to ZA2021/08096A priority patent/ZA202108096B/en
Priority to IL288094A priority patent/IL288094A/en
Priority to IL288095A priority patent/IL288095A/en
Priority to US17/872,974 priority patent/US11723869B2/en
Priority to US18/214,060 priority patent/US20230414517A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes

Definitions

  • the invention relates to a new method of manufacturing a suspension of gas-filled microvesicles by reconstituting a freeze-dried product and to the suspension obtained according to said method.
  • the invention further relates to a new formulation suitable for preparing stable gas-filled microvesicles.
  • a class of contrast agents particularly useful for Contrast Enhanced UltraSound imaging (“CEUS” imaging) includes suspensions of gas bubbles of nano- and/or micro-metric size dispersed in an aqueous medium.
  • the gas is typically entrapped or encapsulated in a film-layer comprising, for instance, emulsifiers, oils, thickeners or sugars.
  • These stabilized gas bubbles are generally referred to in the art with various terminologies, depending typically from the stabilizing material employed for their preparation; these terms include, for instance, “microspheres”, “microbubbles”, “microcapsules” or “microballoons”, globally referred to here as “gas-filled microvesicles” (or “microvesicles”).
  • UltraSound Contrast Agents can be produced according to various manufacturing methods.
  • One of these methods see e.g. WO94/09829, entails the dissolution of an amphiphilic material (such as a phospholipid and/or fatty acid) and of a freeze-drying protecting compound (e.g. polyetheleneglycol) in an organic solvent; the obtained mixture is then subjected to freeze-drying, typically after being filled into vials, to remove the solvent and obtain a freeze-dried product.
  • an amphiphilic material such as a phospholipid and/or fatty acid
  • a freeze-drying protecting compound e.g. polyetheleneglycol
  • Another method see e.g.
  • WO2004/069284 entails the preparation of a microemulsion of water with a water immiscible organic solvent, said emulsion comprising an amphiphilic material and a freeze-drying protecting compound. The emulsion is then and subjected (upon distribution into vials) to a freeze-drying step to remove water and solvent.
  • a suitable gas e.g. a fluorinated gas
  • an aqueous suspension of microbubbles is easily prepared by introducing a suitable liquid into the vial (e.g. saline) and gently shaking the vial to dissolve the freeze-dried product.
  • the Applicant has now observed that the characteristics of a suspension of gas-filled microvesicles (particularly microbubbles) reconstituted from a freeze-dried product can be improved by introducing a final controlled thermal treatment (i.e. heating) at the end of the process for manufacturing the freeze-dried solid product.
  • Applicant has further found a new formulation particularly suitable for preparing stable gas-filled microvesicles, comprising distearoyl-phosphatidylcholine (DSPC), dipalmitoylphosphatidylethanolamine-PEG5000 (DPPE-PEG5000) and palmitic acid in an advantageous relative molar ratio.
  • DSPC distearoyl-phosphatidylcholine
  • DPPE-PEG5000 dipalmitoylphosphatidylethanolamine-PEG5000
  • palmitic acid in an advantageous relative molar ratio.
  • the formulation is useful in particular for therapeutic application with ultrasounds.
  • the invention relates to a method of manufacturing a freeze-dried composition suitable for the preparation of a suspension of stabilized gas-filled microvesicles, said composition comprising: (i) an amphiphilic material capable of stabilizing said gas microvesicles; and (ii) a freeze-drying protecting component; which comprises:
  • said heating step comprises heating said product at a temperature higher than 35° C., more preferably at least 38° C.
  • the heating temperature is preferably lower than 50° C., more preferably lower than 48° C.
  • the invention relates to a freeze-dried product obtained according to the manufacturing method described above.
  • the invention relates to a suspension of gas-filled microvesicles obtained by reconstituting a freeze-dried product prepared according to the method of manufacturing described above, said suspension being obtained by admixing said product with a pharmaceutically acceptable liquid carrier in the presence of a physiologically acceptable gas under gentle agitation.
  • the invention relates to method for manufacturing a suspension of gas-filled microvesicles stabilized by an amphiphilic material, which comprises:
  • the invention relates to a gas-filled microvesicle comprising distearoyl-phosphatidylcholine (DSPC), dipalmitoylphosphatidylethanolamine conjugated with polyethyleneglycol having a Mw of 5000 g/mol (DPPE-PEG5000) and palmitic acid, wherein said components are in a respective relative molar ratio of 65-85/4-10/12-22.
  • DSPC distearoyl-phosphatidylcholine
  • DPPE-PEG5000 dipalmitoylphosphatidylethanolamine conjugated with polyethyleneglycol having a Mw of 5000 g/mol
  • palmitic acid wherein said components are in a respective relative molar ratio of 65-85/4-10/12-22.
  • the molar ratio is of 70-80/5-9/15-21 and more preferably of about 72-76/6-8/16-20, particularly preferred being a molar ratio of 74 (+/ ⁇ 1)/7.5 (+/ ⁇ 0.5)/18.5(+/ ⁇ 1).
  • a further aspect relates to a freeze-dried formulation
  • a freeze-drying protecting component preferably PEG4000.
  • the mixture of the three compounds mentioned above is preferably of from 0.08% to 0.3% by weight with respect to the total amount of freeze-drying protecting component, more preferably from about 0.10% to 0.20% by weight, and even more preferably from 0.12% to 0.18% by weight, particularly preferred being an amount of about 0.16% (w/w) with respect to PEG4000.
  • Another aspect relates to a sealed vial comprising said freeze-dried formulation in contact with a physiologically acceptable gas, preferably perfluorobutane, more preferably in admixture with nitrogen (e.g. 35/65 v/v).
  • a physiologically acceptable gas preferably perfluorobutane, more preferably in admixture with nitrogen (e.g. 35/65 v/v).
  • FIG. 1 shows the relative amount of DPPE-PEG5000 in suspensions of native gas-filled microvesicles, compared to the amount of DPPE-PEG5000 in suspensions of washed gas-filled microvesicles, as discussed in Example 7.
  • a suitable method for preparing injectable suspensions of gas-filled microvesicles comprises the reconstitution, in the presence of a suitable physiologically acceptable gas, of a freeze-dried product comprising an amphiphilic material capable of stabilizing said microvesicles (e.g. by forming a stabilizing layer at the liquid-gas interface) with an aqueous carrier.
  • the freeze-dried product is typically obtained by freeze-drying a liquid mixture comprising said amphiphilic material and a freeze-drying protecting component in a suitable solvent.
  • the liquid mixture which undergoes the freeze-drying process can be obtained according methods know in the art, disclosed e.g. in WO94/09829 or WO2004/069284.
  • the amphiphilic material is dispersed into an organic solvent (e.g. tertiary butanol, dioxane, cyclohexanol, tetrachlorodifluoro ethylene or 2-methyl-2-butanol) together with a suitable freeze-drying protecting component.
  • an organic solvent e.g. tertiary butanol, dioxane, cyclohexanol, tetrachlorodifluoro ethylene or 2-methyl-2-butanol
  • the dispersion containing the amphiphilic material and the freeze-drying protecting component is then subjected to freeze-drying to remove the organic solvent thus obtaining a freeze-dried product.
  • a composition comprising an amphiphilic material may be dispersed in an emulsion of water with a water immiscible organic solvent under agitation, preferably in admixture with a freeze-drying protecting component.
  • Suitable water immiscible organic solvents include, for instance, branched or linear alkanes, alkenes, cyclo-alkanes, aromatic hydrocarbons, alkyl ethers, ketones, halogenated hydrocarbons, perfluorinated hydrocarbons or mixtures thereof.
  • the emulsion may be obtained by submitting the aqueous medium and the solvent, in the presence of the amphiphilic material, to any appropriate emulsion-generating technique known in the art such as, for instance, sonication, shaking, high pressure homogenization, micromixing, membrane emulsification, high speed stirring or high shear mixing.
  • the freeze-drying protecting component can be added either before or after the formation of the emulsion, e.g. as an aqueous solution comprising such freeze-drying protecting component.
  • microemulsion which contains microdroplets of solvent surrounded and stabilized by the amphiphilic material, is then freeze-dried according to conventional techniques to obtain a freeze-dried material, which can then be used for preparing a suspension of gas-filled microvesicles.
  • amphiphilic materials useful for preparing the above liquid mixtures comprise a phospholipid.
  • Phospholipids, as other amphiphilic molecules, are generally capable of forming a stabilizing film of material (typically in the form of a mono-molecular layer) at the gas-water boundary interface in the final gas-filled microvesicles suspension, these materials are also referred to in the art as “film-forming” materials.
  • Phospholipids typically contain at least one phosphate group and at least one, preferably two, lipophilic long-chain hydrocarbon group.
  • Suitable phospholipids include esters of glycerol with one or preferably two (equal or different) residues of fatty acids and with phosphoric acid, wherein the phosphoric acid residue is in turn bound to a hydrophilic group, such a, for instance, choline (phosphatidylcholines—PC), serine (phosphatidylserines—PS), glycerol (phosphatidylglycerols—PG), ethanolamine (phosphatidylethanolamines—PE), inositol (phosphatidylinositol).
  • choline phosphatidylcholines—PC
  • PS serine
  • glycerol phosphatidylglycerols—PG
  • ethanolamine phosphatidylethanolamines—PE
  • inositol phosphatidylinositol
  • Esters of phospholipids with only one residue of fatty acid are generally referred to in the art as the “lyso” forms of the phospholipid or “lysophospholipids”.
  • Fatty acids residues present in the phospholipids are in general long chain aliphatic acids, typically containing from 12 to 24 carbon atoms, preferably from 14 to 22; the aliphatic chain may contain one or more unsaturations or is preferably completely saturated.
  • suitable fatty acids included in the phospholipids are, for instance, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, oleic acid, linoleic acid, and linolenic acid.
  • saturated fatty acids such as myristic acid, palmitic acid, stearic acid and arachidic acid are employed.
  • phospholipid are phosphatidic acids, i.e. the diesters of glycerol-phosphoric acid with fatty acids; sphingolipids such as sphingomyelins, i.e. those phosphatidylcholine analogs where the residue of glycerol diester with fatty acids is replaced by a ceramide chain; cardiolipins, i.e.
  • esters of 1,3-diphosphatidylglycerol with a fatty acid glycolipids such as gangliosides GM1 (or GM2) or cerebrosides; glucolipids; sulfatides and glycosphingolipids.
  • phospholipid(s) includes either naturally occurring, semisynthetic or synthetically prepared compounds that can be employed either singularly or as mixtures.
  • phospholipids examples include natural lecithins (phosphatidylcholine (PC) derivatives) such as, typically, soya bean or egg yolk lecithins.
  • PC phosphatidylcholine
  • Examples of semisynthetic phospholipids are the partially or fully hydrogenated derivatives of the naturally occurring lecithins.
  • Preferred phospholipids are fatty acids di-esters of phosphatidylcholine, ethylphosphatidylcholine, phosphatidylglycerol, phosphatidic acid, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol or of sphingomyelin.
  • phospholipids are, for instance, dilauroyl-phosphatidylcholine (DLPC), dimyristoyl-phosphatidylcholine (DMPC), dipalmitoyl-phosphatidylcholine (DPPC), diarachidoyl-phosphatidylcholine (DAPC), distearoyl-phosphatidylcholine (DSPC), dioleoyl-phosphatidylcholine (DOPC), 1,2 Distearoyl-sn-glycero-3-Ethylphosphocholine (Ethyl-DSPC), dipentadecanoyl-phosphatidylcholine (DPDPC), 1-myristoyl-2-palmitoyl-phosphatidylcholine (MPPC), 1-palmitoyl-2-myristoyl-phosphatidylcholine (PMPC), 1-palmitoyl-2-stearoyl-phosphatidylcholine (PSPC), 1-stearoyl-2-palmito
  • Suitable phospholipids further include phospholipids modified by linking a hydrophilic polymer, such as polyethyleneglycol (PEG) or polypropyleneglycol (PPG), thereto.
  • PEG polyethyleneglycol
  • PPG polypropyleneglycol
  • Preferred polymer-modified phospholipids include “pegylated phospholipids”, i.e. phospholipids bound to a PEG polymer. Examples of pegylated phospholipids are pegylated phosphatidylethanolamines (“PE-PEGs” in brief) i.e.
  • phosphatidylethanolamines where the hydrophilic ethanolamine moiety is linked to a PEG molecule of variable molecular weight (e.g. from 300 to 20000 daltons, preferably from 500 to 5000 daltons), such as DPPE-PEG (or DSPE-PEG, DMPE-PEG, DAPE-PEG or DOPE-PEG).
  • a PEG molecule of variable molecular weight e.g. from 300 to 20000 daltons, preferably from 500 to 5000 daltons
  • DPPE-PEG or DSPE-PEG, DMPE-PEG, DAPE-PEG or DOPE-PEG.
  • DPPE-PEG5000 refers to DPPE having attached thereto a PEG polymer having a mean average molecular weight of about 5000.
  • DPPE-PEG5000 is N-(Carbonyl-methoxypolyethyleneglycol 5000)-1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine, i.e. a dipalmitoylphosphatidylethanolamine conjugated with a methoxy-terminated polyethyleneglycol having a Mw of 5000 g/mol.
  • the phospholipids may bear a reactive moiety which may then be reacted with a corresponding reactive moiety bearing a suitable active component (e.g. targeting ligand), in order to bind said active component to the microvesicle.
  • suitable reactive moieties include, for instance, reactive groups capable of reacting with an amino group bound to an active component such as isothiocyanate groups (that will form a thiourea bond), reactive esters (to form an amide bond), aldehyde groups (for the formation of an imine bond to be reduced to an alkylamine bond); reactive groups capable of reacting with a thiol group bound to an active component, such as haloacetyl derivatives or maleimides (to form a thioether bond); reactive groups capable of reacting with a carboxylic group bound to an active component, such as amines or hydrazides (to form amide or alkylamide bonds).
  • the amphiphilic compound bearing the reactive moiety is a lipid bearing a hydrophilic polymer, such as those previously mentioned, preferably a pegylated phospholipid, e.g. DPPE-PEG2000, such as DPPE-PEG2000-maleimide.
  • a hydrophilic polymer such as those previously mentioned, preferably a pegylated phospholipid, e.g. DPPE-PEG2000, such as DPPE-PEG2000-maleimide.
  • Particularly preferred phospholipids are DAPC, DSPC, DPPC, DMPA, DPPA, DSPA, DMPG, DPPG, DSPG, DMPS, DPPS, DSPS and Ethyl-DSPC. Most preferred are DPPG, DPPS and DSPC.
  • Mixtures of phospholipids can also be used, such as, for instance, mixtures of DPPE and/or DSPE (including pegylated derivates), DPPC, DSPC and/or DAPC with DSPS, DPPS, DSPA, DPPA, DSPG, DPPG, Ethyl-DSPC and/or Ethyl-DPPC.
  • the phospholipids can conveniently be used in admixture with any other compound, preferably amphiphilic.
  • lipids such as cholesterol, ergosterol, phytosterol, sitosterol, lanosterol, tocopherol, propyl gallate or ascorbyl pa Imitate, fatty acids such as myristic acid, palmitic acid, stearic acid, arachidic acid and derivatives thereof or butylated hydroxytoluene and/or other non-phospholipid (amphiphilic) compounds can optionally be added to one or more of the foregoing phospholipids, e.g. in proportions preferably below 50% by weight, more preferably up to 25% or lower.
  • fatty acids useful in a composition according to the invention, which can be either saturated or unsaturated, comprise a C 10 -C 24, aliphatic chain terminated by a carboxylic acid moiety, preferably a C 14 -C 22 and more preferably a C 16 -C 20 aliphatic chain.
  • saturated fatty acids examples include capric (n-decanoic), lauric (n-dodecanoic), myristic (n-tetradecanoic), palmitic (n-hexadecanoic), stearic (n-octadecanoic), arachidic (n-eicosanoic), behenic (n-docosanoic) and n-tetracosanoic acid.
  • Preferred saturated fatty acids are myristic, palmitic, stearic and arachidic acid, more preferably palmitic acid.
  • Examples of unsaturated fatty acids comprise myristoleic (cis-9-tetradecenoic), palmitoleic (cis-9-hexadecenoic), sapienic (cis-6-hexadecenoic), oleic (cis-9-octadecenoic), linoleic (cis-9,12-octadecadienoic), linolenic (cis-9,12,15-octadecatrienoic), gondoic (cis-11-eicosenoic), cis-11,14-eicosadienoic, cis-5,8,11-eicosatrienoic, cis-8,11,14-eicosatrienoic, cis-11,14,17-eicosatrienoic, arachidonic (cis-8,11,14,17-eicosatetraenoic) and erucic (cis-13-docosenoic) acid.
  • the mixture of amphiphilic materials comprises a mixture of DSPC, DPPG and palmitic acid.
  • the above components are preferably in a relative molar ratio (DSPC/DPPG/Palmitic acid) of 25-45/30-50/15-35 (i.e. from 25 to 45% molar amount of DSPC; from 30 to 50% molar amount of DPPG; and from 15 to 35% molar amount of palmitic acid; the total amount of components being 100%), more preferably 30-42/34-46/18-32 and even more preferably 36-38/38-40/23-25 .
  • said amphiphilic material comprises a mixture of DSPC, DPPE-PEG5000 and palmitic acid, optionally further comprising a targeting ligand.
  • the above components are preferably in a relative molar ratio (DSPC/PE-PEG/Palmitic acid) of 60-90/2-10/5-30, more preferably 70-80/3-9/10-25 and even more preferably of about 72-76/6-8/16-20.
  • the mixture further comprises a targeting ligand (e.g.
  • the relative molar ratio of the DSPC/PE-PEG/Palmitic acid components can be of 85-97/2-10/0.2-3, preferably 85-96/3-8/0.3-2 and even more preferably 92-95/4-6/0.4-0.8;
  • the relative molar amount of the targeting ligand (up to a total of 100% together with the above three components) can be from 0.2% to 3%, preferably from 0.3% to 2% and even more preferably 0.4% to 1%.
  • Applicant has unexpectedly found that by suitably modulating the respective molar ratios of the (lipid) components of a composition comprising DSPC, DPPE-PEG and palmitic acid, it is possible to prepare gas-filled microvesicles with improved properties, among others in term of resistance to pressure.
  • the Applicant has found in particular that higher resistance to pressure is conferred to gas-filled microvesicles having compositions comprising a molar amount of palmitic acid (with respect to the other two components) of at least 8%, preferably at least 12%, more preferably at least 15% and even more preferably higher than 16%, but not higher than 22%, preferably not higher than 21%, more preferably not higher than 20% and even more preferably lower than 20%.
  • said amount is of 18.5% (+/ ⁇ 1), more preferably 18.5% (+/ ⁇ 0.5).
  • the Applicant has observed that increasing amounts of DPPE-PEG incorporated into the formulation allow to obtain microvesicles with improved characteristics, such as size distribution (characterized in particular by reduced D v50 and D N values) and lower amounts of large microvesicles (expressed as number of bubbles with size larger than 8 ⁇ m).
  • Applicant has also observed that molar amounts of DPPE-PEG5000 higher than 8% are often not effectively incorporated into the stabilizing layer of the formed microvesicles.
  • formulations comprising excessive amounts of DPPE-PEG5000 may result in microvesicles having increasing amounts of large microvesicles.
  • the Applicant has determined that the relative molar amount of DPPE-PEG5000 (with respect to the other two components) shall be of at least 4%, preferably at least 5%, more preferably at least 6% and even more preferably higher than 6%, but not higher than 10%, preferably not higher than 9%, more preferably not higher than 8% and even more preferably lower than 8%.
  • said amount is of 7.4% (+/ ⁇ 0.5), more preferably 7.4% (+/ ⁇ 0.4).
  • the Applicant has found that its relative molar amount with respect to the other two components, also considering the above illustrated relative ratios, shall be of at least 65%, preferably at least 70%, more preferably at least 72% and even more preferably higher than 72%, but not higher than 85%, preferably not higher than 80%, more preferably not higher than 76% and even more preferably lower than 76%. In a particularly preferred embodiment, said amount is of 74% (+/ ⁇ 1), more preferably 74% (+/ ⁇ 0.8).
  • Preferred embodiments of the invention are compositions comprising DSPC/DPPE-PEG/Palmitic acid in a respective molar amount of 65-85/4-10/8-22 (expressed as relative % molar amounts, the total being 100%).
  • the molar amount is of 70-80/5-9/12-21 and more preferably of about 72-76/6-8/15-20, particularly preferred being a molar ratio of 74 (+/ ⁇ 1)/7.5 (+/ ⁇ 0.5)/18.5(+/ ⁇ 1).
  • the above formulation is generally prepared as a freeze-dried product, according to a freeze-drying process as illustrated herein.
  • the freeze-dried product comprises a suitable freeze-drying protecting component, preferably PEG4000.
  • the amount of freeze-drying protecting component (particularly PEG4000) with respect to the three lipid components shall be relatively high.
  • the total weight of the three lipid components of the formulation is from 0.08% to 0.3% by weight with respect to the total amount of freeze-drying protecting component, preferably from about 0.10% to 0.20% by weight, more preferably from 0.12% to 0.18% by weight, even more preferably of about 0.16%.
  • this relatively high amount of freeze-drying protecting component allows a suitably homogeneous dispersion of the components of the formulation in the freeze-dried mass of the component, particularly when prepared according to the manufacturing method disclosed in WO2004/069284.
  • D N is the mean diameter in number of a population of microvesicles
  • D v50 is the median diameter in volume of a said population of microvesicles, indicating that half of the total gas contained in the population is present in microvesicles having a diameter lower than D v50 .
  • the ratio D v50 /D N provides a general indication about the polydispersity of the population: typically, the lower the D v50 /D N ratio, the narrower the size distribution.
  • the above values of D v50 , D N (as well as other parameters such as total number of microvesicles) can be obtained by measurement with a Coulter counter (e.g. a Coulter Counter Mark II apparatus fitted with a 30 ⁇ m aperture, with a measuring range of 0.7 to 20 ⁇ m).
  • compositions and microvesicles according to the invention may optionally comprise a targeting ligand.
  • targeting ligand includes within its meaning any compound, moiety or residue having, or being capable to promote, a targeting activity (e.g. including a selective binding) of the microvesicles of a composition of the invention towards any biological or pathological site within a living body.
  • Targets with which targeting ligand may be associated include tissues such as, for instance, myocardial tissue (including myocardial cells and cardiomyocytes), membranous tissues (including endothelium and epithelium), laminae, connective tissue (including interstitial tissue) or tumors; blood clots; and receptors such as, for instance, cell-surface receptors for peptide hormones, neurotransmitters, antigens, complement fragments, and immunoglobulins and cytoplasmic receptors for steroid hormones.
  • tissues such as, for instance, myocardial tissue (including myocardial cells and cardiomyocytes), membranous tissues (including endothelium and epithelium), laminae, connective tissue (including interstitial tissue) or tumors; blood clots; and receptors such as, for instance, cell-surface receptors for peptide hormones, neurotransmitters, antigens, complement fragments, and immunoglobulins and cytoplasmic receptors for ste
  • the targeting ligand may be synthetic, semi-synthetic, or naturally-occurring.
  • Materials or substances which may serve as targeting ligands include, for example, but are not limited to proteins, including antibodies, antibody fragments, receptor molecules, receptor binding molecules, glycoproteins and lectins; peptides, including oligopeptides and polypeptides; peptidomimetics; saccharides, including mono and polysaccharides; vitamins; steroids, steroid analogs, hormones, cofactors, bioactive agents and genetic material, including nucleosides, nucleotides and polynucleotides.
  • the targeting ligand may be a compound per se which is admixed with the other components of the microvesicle or may be a compound which is bound to an amphiphilic molecule (typically a phospholipid) employed for the formation of the microvesicle.
  • an amphiphilic molecule typically a phospholipid
  • the targeting ligand may be bound to an amphiphilic molecule (e.g. a phospholipid) forming the stabilizing envelope of the microvesicle through a covalent bond.
  • an amphiphilic molecule e.g. a phospholipid
  • the specific reactive moiety that needs to be present on the amphiphilic molecule will depend on the particular targeting ligand to be coupled thereto, as illustrated in detail above.
  • at least part of the amphiphilic compound forming the microvesicle's envelope shall thus contain a suitable reactive moiety and the targeting ligand containing the complementary functionality will be linked thereto according to known techniques, e.g.
  • the amphiphilic compound is a lipid bearing a hydrophilic polymer, such as those previously mentioned, preferably a pegylated phospholipid (e.g. DSPE-PEG2000).
  • the targeting ligand is linked to a suitable reactive moiety on the hydrophilic polymer (e.g. DSPE-PEG2000-NH 2 ), optionally through a linker (e.g. .
  • the amphiphilic compound may be combined with the desired targeting ligand before preparing the microvesicle, and the so obtained combination may be used for the preparation of the microvesicle.
  • the targeting ligand may be linked to the respective amphiphilic compound during the preparation of the microvesicle (e.g. in the intermediate microemulsion preparation of the process described in WO2004/069284).
  • the binding may take place on the formed microvesicle comprising an amphiphilic material bearing a reactive moiety.
  • the targeting ligand may also be suitably associated with the microvesicle via physical and/or electrostatic interaction.
  • a functional moiety having a high affinity and selectivity for a complementary moiety may be introduced into the amphiphilic molecule, while the complementary moiety will be linked to the targeting ligand.
  • an avidin (or streptavidin) moiety having high affinity for biotin
  • an avidin (or streptavidin) moiety having high affinity for biotin
  • a suitable targeting ligand e.g. a peptide or an antibody.
  • the biotin-labelled targeting ligand will thus be associated with the avidin-labelled phospholipid of the microvesicle by means of the avidin-biotin coupling system.
  • both the phospholipid and the targeting ligand may be provided with a biotin moiety and subsequently coupled to each other by means of avidin (which is a bifunctional component capable of bridging the two biotin moieties).
  • avidin which is a bifunctional component capable of bridging the two biotin moieties.
  • Examples of biotin/avidin coupling of phospholipids and peptides are also disclosed in the above cited U.S. Pat. No. 6,139,819.
  • van der Waal's interactions, electrostatic interactions and other association processes may associate with or bind to the targeting ligand to the amphiphilic molecules.
  • the phospholipid may be modified with a protein suitable for specific coupling to Fc domain of Immunoglubulin (Ig) such as Protein A, Protein G, Protein A/G or Protein L.
  • the targeting ligand may be a compound which is admixed with the components forming the microvesicle, to be eventually incorporated the microvesicle structure, such as, for instance, a lipopeptide as disclosed e.g. in International patent Applications WO 98/18501 or 99/55383.
  • a microvesicle may first be manufactured, which comprises a compound (lipid or polymer-modified lipid) having a suitable moiety capable of interacting with a corresponding complementary moiety of a targeting ligand; thereafter, the desired targeting ligand is added to the microvesicle suspension, to bind to the corresponding complementary moiety on the microvesicle.
  • a compound lipid or polymer-modified lipid
  • Suitable specific targets to which the microvesicles may be directed are, for instance, fibrin and the GPIIbIIIa binding receptor on activated platelets. Fibrin and platelets are in fact generally present in “thrombi”, i.e. coagula which may form in the blood stream and cause a vascular obstruction.
  • thrombi i.e. coagula which may form in the blood stream and cause a vascular obstruction.
  • Suitable binding peptides are disclosed, for instance, in the above cited U.S. Pat. No. 6,139,819. Further binding peptides specific for fibrin-targeting are disclosed, for instance, in International patent application WO 02/055544.
  • kinase domain region KDR
  • VEGF vascular endothelial growth factor
  • Binding peptides suitable for KDR or VEGF/KDR complex are disclosed, for instance, in International Patent application WO 03/74005, WO 3/084574 and WO2007/067979.
  • the targeting peptide is a dimeric peptide-phospholipid conjugate (lipopeptide) as described in WO2007/067979.
  • a freeze-drying protecting component is a compound with cryoprotective and/or lyoprotective effect.
  • suitable freeze-drying protecting components include, for instance, carbohydrates, e.g. a mono- di- or poly-saccharide, such as sucrose, maltose, trehalose, glucose, lactose, galactose, raffinose, cyclodextrin, dextran, chitosan and its derivatives (e.g. carboxymethyl chitosan, trimethyl chitosan); polyols, e.g. sugar alcohols such as sorbitol, mannitol or xylitol; or hydrophilic polymers, e.g.
  • polyoxyalkyleneglycol such as polyethylene glycol (e.g. PEG2000, PEG4000 or PEG8000) or polypropylenglycol.
  • said freeze-drying protecting component is polyethylene glycol, preferably PEG4000.
  • PEG4000 as used herein has its normal meaning in the field, indicating a polyethyleneglycol having a molecular weight of about 4000 g/mole, in general with a variation of +/ ⁇ 10% around said value.
  • the liquid mixture containing the amphiphilic material and the freeze-drying protecting component (obtained e.g. according to either of the previously illustrated manufacturing processes), is typically sampled into glass vials (e.g. DIN8R) which are loaded into a freeze-dryer.
  • the freeze-drying process generally includes an initial step (primary drying) where the vials are rapidly deep-cooled (e.g. at temperatures of from ⁇ 35° C. to ⁇ 70° C.) to freeze the liquid(s) of the mixture and then subjected to vacuum (e.g. 0.1-0.8 mbar); during the primary drying, the substantial totality of the frozen liquid(s) (e.g.
  • water and/or solvents is removed by sublimation, typically up to about 95% of the total amount of liquid, preferably up to about 99%.
  • residual liquid including possible interstitial water
  • the temperature during the secondary drying is preferably not higher than 35° C.
  • the secondary drying can be stopped when the residual content of the liquid(s) reaches a desired minimum value, e.g. less 3% (preferably less than 1%) by weight of water with respect to the total mass of residual freeze-dried product, or e.g. less than 0.01% by weight, preferably less than 0.08%, for residual solvent(s).
  • the freeze-dried product can undergo the additional thermal treatment step according to the invention.
  • the thermal treatment is performed on the sealed vial, after saturating the headspace of the vials containing the freeze-dried product with a suitable physiologically acceptable gas and then stoppering (e.g. with a rubber, such as butyl rubber, stopper) and sealing (e.g. with a metal, such as aluminium, crimp seal) the vials.
  • the vials are preferably removed from the freeze-drier and introduced in a suitable oven for the thermal treatment.
  • such thermal treatment can be performed on the open vial (which is preferably kept into the freeze-dryer), which is then saturated with the gas and then stoppered/sealed.
  • physiologically acceptable gases include, for instance, fluorinated gases such as SF 6, C 3 F 8 , C 4 F 10 , optionally in admixture with air or nitrogen.
  • the gas SF 6 is used in combination with a mixture of amphiphilic materials comprising DSPC, DPPG and palmitic acid, as above defined.
  • the gas C 4 F 10 is used in combination with a mixture of amphiphilic materials comprising DSPC, DPPE-PEG5000 and palmitic acid, optionally further comprising a targeting ligand, as above defined.
  • excipients or additives may either be present in the dry formulation for the preparation of the microvesicles or may be added together with the aqueous carrier used for the reconstitution thereof, without necessarily being involved (or only partially involved) in the formation of the stabilizing envelope of the microvesicle.
  • excipients or additives include for instance pH regulators, osmolality adjusters, viscosity enhancers, emulsifiers, bulking agents, etc. and may be used in conventional amounts.
  • the suspension of gas-filled microvesicles can then be prepared by reconstituting the freeze-dried product with a physiologically acceptable (aqueous) carrier, under gentle agitation.
  • physiologically acceptable (aqueous) carriers include, for instance, water for injection, saline or glucose solution, optionally containing excipients or additives as illustrated above.
  • the freeze-dried product (contained in respective vials at the end of the freeze-drying process) advantageously undergoes an additional final step of heat treatment (or thermal treatment).
  • the thermal treatment is preferably performed on the freeze-dried product in the sealed vials already containing the physiologically acceptable gas
  • the thermal treatment can be either accomplished within the freeze-drier apparatus or preferably in a separate heating device (e.g. an oven).
  • the heating step is preferably performed within the lyophilizing apparatus; afterward, the atmosphere is saturated with the desired gas and the vials are sealed.
  • said heat treatment of the freeze-dried product surprisingly results in improved characteristics of the suspension of gas-filled microvesicles obtained upon reconstituting of the freeze-dried product, with respect to suspensions obtained from freeze-dried products which do not undergo such heat treatment.
  • Applicant observed in particular that such treatment results in an increased resistance to pressure of the obtained microvesicles.
  • the freeze-dried product is preferably heated at a temperature higher than 35° C. (e.g. 36° C.), more preferably at a temperature of 38° C. or higher.
  • the maximum temperature of the heat treatment generally depends on the materials comprised in the freeze-dried product. For instance, such temperature shall be lower than the melting point of the material used as freeze-drying additive, which is the component forming most of the mass of the freeze-dried product (typically from 50 up to more than 600 times the weight of the active components forming the stabilizing layer of the microvesicles).
  • PEG4000 has a melting temperature of 53-58° C.
  • the heating temperature is preferably of 50° C. or lower.
  • Preferred temperatures for the heat treatment are from 38° C. to 45° C.
  • the duration of the heat treatment generally depends on the temperature of the treatment; typically, the higher the temperature, the shorter the duration of the heating.
  • the duration of the heat treatment shall not be unnecessarily prolonged. While a treatment duration of about 8 hours may be sufficient (particularly in combination with temperatures higher than 45° C., e.g. 48° C.), the duration of the heat treatment is preferably performed during 12 hours, up to e.g. 20 hours, more preferably 14 to 18 hours.
  • the freeze-dried product comprises a mixture of a phospholipid and of a fatty acid, as above defined, in admixture with a freeze-drying protecting component.
  • the thermal treatment of the invention has been proven to be particularly effective for improving the characteristics of gas-filled microvesicles comprising such mixture of components.
  • the freeze-dried product comprises DSPC, DPPG and palmitic acid in combination with a freeze-drying protecting component (e.g., polyetheleneglycol, such as PEG4000).
  • Said freeze-dried product is preferably heated at a temperature of from about 40° C. to 48° C., particularly of about 45° C. (+/ ⁇ 3° C.) for at least eight hours, preferably for about 18 h (+/ ⁇ 4h).
  • the freeze-dried product comprises DSPC, DPPE-PEG5000 and palmitic acid in combination with a freeze-drying protecting component (e.g. polyetheleneglycol, such as PEG4000).
  • a freeze-drying protecting component e.g. polyetheleneglycol, such as PEG4000.
  • Said freeze-dried product is heated at a temperature of from about 36° C. to 45° C., particularly of about 39° C. (+/ ⁇ 3° C.) for at least eight hours, preferably for about 15 h (+/ ⁇ 5h).
  • said mixture of DSPC, DPPE-PEG5000 and palmitic acid further comprises a targeting lipopeptide, e.g. as described in WO2007/067979.
  • the thermal treatment of the freeze-dried product according to the invention results in an increased resistance of the gas-filled microvesicles to pressure.
  • microvesicles with increased resistance to pressure generally show an increased time persistency in the blood stream once injected.
  • Resistance to pressure of gas-filled microvesicles can be assessed by determining the empiric parameter “Pc50” or “critical pressure”.
  • the Pc50 of a suspension of gas-filled microvesicles identifies the value of applied overpressure (with respect to atmospheric pressure) at which the absorbance of a suspension of microvesicles drops to half of the absorbance of the suspension measured at atmospheric pressure, said applied overpressure resulting in a substantial reduction of the population of microvesicles with respect to the initial one (at atmospheric pressure).
  • reduction of the absorbance of a suspension of microvesicles is related to the reduction of the initial population of gas-filled microvesicles, whereby the initially milky suspension (high concentration of microvesicles) becomes more and more transparent under increasing pressure (reduced concentration due to collapse of microvesicles).
  • a minimum Pc50 value of at least 12 kPa is desirable for gas-filled microvesicles, preferably at least 13 kPa (about 100 mmHg), more preferably at least 14 kPa (105 mmHg).
  • a minimum Pc50 value of at least 55 kPa is desirable, preferably at least 70 kPa (about 525 mmHg), more preferably at least 80 kPa (about 600 mmHg), while higher values of Pc50 are even more preferred.
  • the thermal treatment of the freeze-dried product according to the invention allows increasing the Pc50 of the reconstituted suspension of microvesicles of at least 5 kPa, preferably at least 8 kPa and more preferably at least 10 kPa with respect to the Pc50 of a reconstituted suspension obtained from a freeze-dried product which has not been submitted to such thermal treatment.
  • Such increase of Pc50 may be up to 15 kPa and in some embodiments up to 25 kPa.
  • a suspension of microvesicles reconstituted from freeze-dried product subjected to a thermal treatment according to the invention has a value of Pc50 of at least 20 kPa, preferably at least 22 kPa and more preferably of at least 25 kPa.
  • a suspension of microvesicles reconstituted from a freeze-dried product subjected to a thermal treatment according to the invention has a value of Pc50 of at least at least 75 kPa, preferably at least 80 kPa and more preferably of at least 90 kPa.
  • the vials containing the freeze-dried product can be advantageously packaged in a two component diagnostic and/or therapeutic kit, preferably for administration by injection.
  • the kit preferably comprises the vial containing the freeze-dried product and a second container (e.g. a syringe barrel) containing the physiologically acceptable aqueous carrier for reconstitution.
  • microvesicles of the present invention may be used in a variety of diagnostic and/or therapeutic techniques, including in particular ultrasound.
  • An aspect of the invention thus relates to the use in a method of diagnosing of a suspension of microvesicles reconstituted from freeze-dried product subjected to a thermal treatment according to the invention.
  • Diagnostic methods include any method where the use of the gas-filled microvesicles allows enhancing the visualisation of a portion or of a part of an animal (including humans) body, including imaging for preclinical and clinical research purposes.
  • imaging techniques may be employed in ultrasound applications, for example including fundamental and harmonic B-mode imaging, pulse or phase inversion imaging and fundamental and harmonic Doppler imaging; if desired three-dimensional imaging techniques may be used.
  • Microvesicles according to the invention may typically be administered in a concentration of from about 0.01 to about 1.0 ⁇ L of gas per kg of patient, depending e.g. on their respective composition, the tissue or organ to be imaged and/or the chosen imaging technique.
  • This general concentration range may of course vary depending on specific imaging applications, e.g. when signals can be observed at very low doses such as in colour Doppler or power pulse inversion.
  • said suspension of gas-filled microvesicles comprises DSPC, DPPG, palmitic acid and PEG4000.
  • Reconstitution of the freeze-dried product is preferably made by dispersing it into a physiologically acceptable aqueous carrier, e.g. saline, in the presence of a physiologically acceptable gas, e.g SF 6, under gentle agitation.
  • a physiologically acceptable aqueous carrier e.g. saline
  • Said suspension of microvesicles has preferably a value of Pc50 of at least 20 kPa, more preferably at least 22 kPa and even more preferably of at least 25 kPa.
  • said method of diagnosing comprises ultrasound imaging of the heart, in particular to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border in adult patients with suboptimal echocardiograms.
  • said method of diagnosing comprises ultrasound imaging of the liver, in particular for characterization of focal liver lesions in adult and pediatric patients.
  • said method of diagnosing comprises ultrasound imaging of the urinary tract, particularly for the evaluation of suspected or known vesicoureteral reflux in pediatric patients.
  • said suspension of gas-filled microvesicles comprise DSPC, DPPE-PEG5000, palmitic acid, optionally a targeting lipopeptide and PEG4000.
  • the targeting lipopeptide is a VEGF/KDR targeting lipopeptide, e.g. as described in WO2007/067979.
  • Possible other diagnostic imaging applications include scintigraphy, light imaging, and X-ray imaging, including X-ray phase contrast imaging.
  • Another aspect of the invention relates to the use in a method of therapeutic treatment of a suspension of microvesicles reconstituted from freeze-dried product subjected to a thermal treatment according to the invention.
  • Therapeutic techniques include any method of treatment (as above defined) of a patient which comprises the combined use of ultrasounds and gas-filled microvesicles either as such (e.g. in ultrasound mediated thrombolysis, high intensity focused ultrasound ablation, blood-brain barrier permeabilization, immunomodulation, neuromudulation, radiosensitization) or in combination with a therapeutic agent (i.e.
  • ultrasound mediated delivery e.g. for the delivery of a drug or bioactive compound to a selected site or tissue, such as in tumor treatment, gene therapy, infectious diseases therapy, metabolic diseases therapy, chronic diseases therapy, degenerative diseases therapy, inflammatory diseases therapy, immunologic or autoimmune diseases therapy or in the use as vaccine), whereby the presence of the gas-filled microvesicles may provide a therapeutic effect itself or is capable of enhancing the therapeutic effects of the applied ultrasounds, e.g. by exerting or being responsible to exert a biological effect in vitro and/or in vivo, either by itself or upon specific activation by various physical methods (including e.g. ultrasound mediated delivery).
  • a drug or bioactive compound to a selected site or tissue, such as in tumor treatment, gene therapy, infectious diseases therapy, metabolic diseases therapy, chronic diseases therapy, degenerative diseases therapy, inflammatory diseases therapy, immunologic or autoimmune diseases therapy or in the use as vaccine
  • the presence of the gas-filled microvesicles may provide a therapeutic effect itself or is capable of enhancing the therapeutic effects of the
  • Microvesicles according to the invention can typically be administered for therapeutic purposes in a concentration of from about 0.01 to about 5.0 ⁇ L of gas per kg of patient, depending e.g. from their respective composition, the type of subject under treatment, the tissue or organ to be treated and/or the therapeutic method applied.
  • said suspension of gas-filled microvesicles comprises DSPC, DPPE-PEG5000, palmitic acid, optionally a targeting lipopeptide and PEG4000.
  • Reconstitution of the freeze-dried product is preferably made by dispersing it into a physiologically acceptable aqueous carrier, e.g. saline, in the presence of a physiologically acceptable gas, e.g. a mixture of C 4 F 10 and nitrogen, under gentle agitation.
  • Said suspension of microvesicles has preferably a value of Pc50 of at least 84 kPa, more preferably at least 88 kPa and even more preferably of at least 90 kPa, up to about e.g. 105 kPa.
  • the suspension of gas-filled microvesicles of the invention may be advantageously used in a method for separating cells, typically by buoyancy (also known as buoyancy-activated cell sorting, “BACS”).
  • the method can be useful for separating a desired type of cells from other cells in a physiological liquid (e.g. blood or plasma).
  • the separation method comprises labelling a desired cell to be separated with a suitable labelled antibody capable of binding to a specific (and selective) receptor on said cell.
  • the microvesicles of the invention are then added to the suspension of cells to be separated (including those bearing the labelled antibody); once admixed to the suspension of cells, the microvesicles associate through the ligand with the labelling residue bound to antibody/cell construct thus allowing separation of the cells by buoyancy (see e.g. WO 2017/117349).
  • the labelled antibody is a biotinylated antibody, where the biotin residue is capable of associating with a respective moiety, such as for instance an avidin, neutravidin or streptavidin residue on a gas-filled microvesicles.
  • the improved resistance to pressure allow using the microvesicles of the invention in a wide variety of methods for separating cells.
  • DPPG-Na 1,2-dipalmitoyl-sn-glycero-3-phospho-(1′-rac-glycerol) (sodium salt)
  • DPPE-PEG5000 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-5000] (ammonium salt)
  • the resistance to pressure of gas-filled microvesicles was evaluated using an in-house developed pressure nephelometer. Briefly, the microvesicles suspension was introduced into a spectrophotometer sample cell (airtight and connected to a pressurization system). The optical density (absorbance at 700 nm) of the suspension is continuously recorded while linearly increasing the pressure applied to the sample in the cell from atmospheric pressure (760 mmHg, 101.3 kPa,) to an over pressure of two bars (2280 mmHg, 303,9 kPa), at a rate of about 4 mmHg/s (533 Pa/s).
  • the Pc50 parameter (“critical pressure”) characterizing each suspension identifies the overpressure (with respect to atmospheric pressure) at which the absorbance of the microvesicles suspension drops to half of its initial value.
  • the size distributions, volume concentrations and number of the microbubbles (after freeze-drying, with or without thermal treatment, and reconstitution with an aqueous phase) were determined by using a Coulter Counter Multisizer 3 apparatus fitted with a 30 pm aperture with a measuring range of 0.7 to 20 ⁇ m. 50 ⁇ l of microbubble samples were diluted in 100 ml of saline at room temperature and allowed to equilibrate for 3 minutes prior to measurement.
  • DSPC, DPPG-Na and palmitic acid in a weight ratio of 4.75/4.75/1 were first dissolved in hexane/ethanol (8/2, v/v) at a concentration of about 5 g/L and the solvents were evaporated under vacuum.
  • the solid residue was admixed with PEG4000 in a weight ratio of about 0.017:1, the mixture was dissolved in tert-butanol at around 60° C. and the clear solution was used to fill respective DIN8R vials (with a corresponding volume containing about 25 mg of the mixture).
  • the vials were then rapidly cooled at ⁇ 45° C. and then subjected the vacuum for removing the frozen solvent by sublimation.
  • the temperature was then raised (above room temperature, not higher than 35° C.) and the remaining solvent was evaporated, down to a final amount of less than 0.5% by weight.
  • the ambient of the freeze-dryer was saturated with SF6 at atmospheric pressure and the vials (containing the solid freeze-dried product in contact with SF6) were stoppered and sealed.
  • an emulsion of cyclooctane and water (about 1.5/100 v/v) containing about 90 mg/I of DSPC, 7 mg/I of palmitic acid, 60 mg/I of DPPE-PEG5000 (molar ratio of about 75/18/7) and 100 g/I of PEG4000 is prepared (Megatron MT3000, Kinematica;
  • the vials were cooled at -50° C. under vacuum and then subjected to lyophilization, followed by secondary drying above room temperature until complete removal of water and solvent (less than 0.5% by weight), as described in example 1.
  • the headspace of the vials is saturated with a 35/65 mixture of C 4 F 10 /N 2 and the vials are stoppered and sealed.
  • the vials of batch la were submitted to a heating temperature of 48° C. for a time ranging from 8 hours to one week (five vials for each group).
  • the product in the vial was then reconstituted with 5 ml of saline and the characteristics of the microvesicles in the suspension were measured. Results are reported in the following table 1.
  • the vials of batch 2 a were submitted to a heating temperature of 40° C. or 45° C. for 16 hours or not heated.
  • the product in the vial was then reconstituted with 5 ml of saline and the characteristics of the microvesicles in the suspension were measured. Results are reported in the following table 3.
  • the vials of batch 2 b were submitted to a heating temperature of 40° C. for a time ranging from 16 to 88 hours, or not heated.
  • the product in the vial was then reconstituted with 5 ml of saline and the characteristics of the microvesicles in the suspension were measured. Results are reported in the following table 4.
  • the vials of batch 2 h were submitted to a heat treatment at 38° C. for a time ranging from two to 24 hours.
  • the product in the vial was then reconstituted with 5 ml of saline and the characteristics of the microvesicles in the suspension were measured.
  • an increasing pressure resistance of the microvesicles in the reconstituted suspension is obtained upon heating the freeze-dried material for an increasing time, up to 8-12 hours at 38° C. Further heating of the material (16 or 24 hours) does not substantially further increase the pressure resistance.
  • DSPC/Palmitic acid/DPPE-PEG Containing Microvesicles 25 mg of a DSPC/Palmitic acid mixture (80/20 molar ratio) are dissolved in cyclooctane (4 mL), at 70° C. for 5 minutes. Separately, DPPE-PEG5000 (16.7 mg) was dissolved in distilled water (1 mL) at 70° C. and a 10% (w/w) PEG4000 solution in distilled water (49 mL) was added thereto.
  • the aqueous phase and the organic phase were emulsified (Megatron MT3000, 10′000 rpm, 3.5 min).
  • the emulsion was recovered in a 100 mL flask (Duran), then heated at 80° C. for 1 hour and finally cooled to room temperature ( ⁇ 1 h).
  • the emulsion was then diluted five folds with the above 10% PEG4000 solution (i.e., 216 mL of 10% PEG4000 solution were added to the 54 mL of the emulsion) and sampled in DIN8R vials (0.75 mL/vial).
  • the relative DSPC/Palmitic acid/DPPE-PEG5000 molar ratio in the emulsion was of about 74/18.5/7.5.
  • the total weight of the three components with respect to the total amount of PEG4000 is of about 0.16%.
  • the vials were cooled at ⁇ 50° C. under vacuum and then subjected to lyophilization, followed by secondary drying above room temperature until complete removal of water and solvent (less than 0.5% by weight), as described in example 1.
  • the headspace of the vials is saturated with a 35/65 mixture of C 4 F 10 /N 2 and the vials are stoppered and sealed.
  • the vials were then heated at 45° C. for 16 hours.
  • the product in the vial was then redispersed in saline (5 mL/vial) upon gentle shaking before use.
  • Example 5 was repeated, by modifying the relative molar amount of palmitic acid with respect to DSPC (i.e. 0, 10, 20, 40 and 60, respectively), maintaining the same amount of DPPE-PEG5000. This corresponds to relative molar amounts of palmitic acid of about 0%, 9.3%, 18.5%, 37.1% and 55.6% in the final formulation.
  • results are reported in the following table 7, showing that amounts of palmitic acid between 10 and 20 provide microvesicles with improved characteristics, particularly in terms of pressure resistance, number of microvesicles and size distribution. Taking into account all the characteristics, formulations with an amount of palmitic acid of about 20% w/r to DSPC are particularly preferred.
  • Example 5 was repeated by varying the amount of DPPE-PEG5000 (0, 1%, 3%, 7.4%, 12%), by maintaining the same amount and ratio of DSPC/palmitic acid. Results are illustrated in Table 8 showing that an amount of DPPE-PEG5000 around 7.4% provides preparation with a reduced number of microvesicles having a diameter larger than 8 microns (Nb Mv>8 ⁇ m), as well as narrower distribution.
  • Example 5 was repeated, but the PEG4000 solution used for the five-fold dilution of the emulsion was used at different concentration, namely 2%, 5%, 10%, 15% and 20% by weight; the total weight of the lipid components with respect to the amount of PEG4000 was thus of about 0.77%, 0.31%, 0.16%, 0.10% and 0.08%, respectively.
  • Results are illustrated in table 9, showing that the use of solutions of PEG4000 at about 10% or higher (resulting in compositions where the total weight of the three components with respect to the total amount of PEG4000 is of about 0.16% or higher, up to about 0.08%) provide suspensions of gas-filled microvesicles with particularly advantageous characteristics (such as relative narrow size distribution, improved pressure resistance and in particular a lower number of large size microvesicles.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Acoustics & Sound (AREA)
  • Radiology & Medical Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Meat, Egg Or Seafood Products (AREA)
US16/788,083 2019-05-15 2020-02-11 Freeze-dried product and gas-filled microvesicles suspension Abandoned US20200360289A1 (en)

Priority Applications (29)

Application Number Priority Date Filing Date Title
US16/788,083 US20200360289A1 (en) 2019-05-15 2020-02-11 Freeze-dried product and gas-filled microvesicles suspension
BR112021022185A BR112021022185A2 (pt) 2019-05-15 2020-05-14 Microvesículas preenchidas com gás
CA3137089A CA3137089A1 (fr) 2019-05-15 2020-05-14 Microvesicules remplies de gaz
BR112021021791A BR112021021791A2 (pt) 2019-05-15 2020-05-14 Produto seco por congelamento e suspensão de microvesículas preenchidas com gás
AU2020276679A AU2020276679A1 (en) 2019-05-15 2020-05-14 Gas-filled microvesicles
SG11202111756UA SG11202111756UA (en) 2019-05-15 2020-05-14 Gas-filled microvesicles
KR1020217037784A KR102624471B1 (ko) 2019-05-15 2020-05-14 가스 충전된 미세소포
KR1020247001478A KR20240010559A (ko) 2019-05-15 2020-05-14 동결 건조 제품 및 가스 충전된 미세소포 현탁액
CN202080035588.8A CN113825529B (zh) 2019-05-15 2020-05-14 充气微泡
PCT/EP2020/063559 WO2020229642A1 (fr) 2019-05-15 2020-05-14 Produit lyophilisé et suspension de microvésicules remplies de gaz
SG11202111754PA SG11202111754PA (en) 2019-05-15 2020-05-14 Freeze-dried product and gas-filled microvesicles suspension
CN202080035142.5A CN113811335A (zh) 2019-05-15 2020-05-14 冻干产品和充气微泡的悬浮液
US17/610,853 US11717570B2 (en) 2019-05-15 2020-05-14 Gas-filled microvesicles
US17/611,034 US11426352B2 (en) 2019-05-15 2020-05-14 Freeze-dried product and gas-filled microvesicles suspension
JP2021567832A JP7357078B2 (ja) 2019-05-15 2020-05-14 ガス充填微小胞
EP20726106.6A EP3969065A1 (fr) 2019-05-15 2020-05-14 Microvésicules remplies de gaz
PCT/EP2020/063560 WO2020229643A1 (fr) 2019-05-15 2020-05-14 Microvésicules remplies de gaz
KR1020217037356A KR102626600B1 (ko) 2019-05-15 2020-05-14 동결 건조 제품 및 가스 충전된 미세소포 현탁액
AU2020274620A AU2020274620A1 (en) 2019-05-15 2020-05-14 Freeze-dried product and gas-filled microvesicles suspension
CA3137088A CA3137088C (fr) 2019-05-15 2020-05-14 Produit lyophilise et suspension de microvesicules remplies de gaz
ES20726105T ES2965028T3 (es) 2019-05-15 2020-05-14 Producto liofilizado y suspensión de microvesículas llenas de gas
JP2021567831A JP7148742B2 (ja) 2019-05-15 2020-05-14 凍結乾燥産物およびガス充填微小胞懸濁液
EP20726105.8A EP3969064B1 (fr) 2019-05-15 2020-05-14 Produit lyophilisé et suspension de microvésicules remplies de gaz
ZA2021/08052A ZA202108052B (en) 2019-05-15 2021-10-20 Freeze-dried product and gas-filled microvesicles suspension
ZA2021/08096A ZA202108096B (en) 2019-05-15 2021-10-21 Gas-filled microvesicles
IL288094A IL288094A (en) 2019-05-15 2021-11-14 Gas-filled microbubbles that include a mixture of lipid components and preparations for their preparation and use
IL288095A IL288095A (en) 2019-05-15 2021-11-14 Freeze-dried product and gas-filled microbubble suspension
US17/872,974 US11723869B2 (en) 2019-05-15 2022-07-25 Freeze-dried product and gas-filled microvesicles suspension
US18/214,060 US20230414517A1 (en) 2019-05-15 2023-06-26 Freeze-dried product and gas-filled microvesicles suspension

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201916413526A 2019-05-15 2019-05-15
US16/688,540 US20200360540A1 (en) 2019-05-15 2019-11-19 Freeze-dried product and gas-filled microvesicles suspension
US16/788,083 US20200360289A1 (en) 2019-05-15 2020-02-11 Freeze-dried product and gas-filled microvesicles suspension

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US16/688,540 Continuation-In-Part US20200360540A1 (en) 2019-05-15 2019-11-19 Freeze-dried product and gas-filled microvesicles suspension

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US17/611,034 Continuation US11426352B2 (en) 2019-05-15 2020-05-14 Freeze-dried product and gas-filled microvesicles suspension
US17/610,853 Continuation-In-Part US11717570B2 (en) 2019-05-15 2020-05-14 Gas-filled microvesicles
PCT/EP2020/063559 Continuation WO2020229642A1 (fr) 2019-05-15 2020-05-14 Produit lyophilisé et suspension de microvésicules remplies de gaz

Publications (1)

Publication Number Publication Date
US20200360289A1 true US20200360289A1 (en) 2020-11-19

Family

ID=70738571

Family Applications (4)

Application Number Title Priority Date Filing Date
US16/788,083 Abandoned US20200360289A1 (en) 2019-05-15 2020-02-11 Freeze-dried product and gas-filled microvesicles suspension
US17/611,034 Active US11426352B2 (en) 2019-05-15 2020-05-14 Freeze-dried product and gas-filled microvesicles suspension
US17/872,974 Active US11723869B2 (en) 2019-05-15 2022-07-25 Freeze-dried product and gas-filled microvesicles suspension
US18/214,060 Pending US20230414517A1 (en) 2019-05-15 2023-06-26 Freeze-dried product and gas-filled microvesicles suspension

Family Applications After (3)

Application Number Title Priority Date Filing Date
US17/611,034 Active US11426352B2 (en) 2019-05-15 2020-05-14 Freeze-dried product and gas-filled microvesicles suspension
US17/872,974 Active US11723869B2 (en) 2019-05-15 2022-07-25 Freeze-dried product and gas-filled microvesicles suspension
US18/214,060 Pending US20230414517A1 (en) 2019-05-15 2023-06-26 Freeze-dried product and gas-filled microvesicles suspension

Country Status (13)

Country Link
US (4) US20200360289A1 (fr)
EP (2) EP3969064B1 (fr)
JP (2) JP7357078B2 (fr)
KR (3) KR20240010559A (fr)
CN (2) CN113811335A (fr)
AU (2) AU2020276679A1 (fr)
BR (2) BR112021021791A2 (fr)
CA (2) CA3137088C (fr)
ES (1) ES2965028T3 (fr)
IL (2) IL288095A (fr)
SG (2) SG11202111756UA (fr)
WO (2) WO2020229642A1 (fr)
ZA (2) ZA202108052B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200360289A1 (en) * 2019-05-15 2020-11-19 Bracco Suisse Sa Freeze-dried product and gas-filled microvesicles suspension
US11717570B2 (en) * 2019-05-15 2023-08-08 Bracco Suisse Sa Gas-filled microvesicles
CN115970010A (zh) * 2021-10-14 2023-04-18 北京启慧生物医药有限公司 脂质微泡冻干粉组合物及其制备方法
WO2023111332A1 (fr) 2021-12-16 2023-06-22 Bracco Suisse Sa Procédé d'extraction d'un gaz fluoré
WO2024133827A1 (fr) 2022-12-21 2024-06-27 Bracco Suisse Sa Microvésicules remplies de gaz avec perfluoro-oléfine

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010008626A1 (en) * 1990-04-02 2001-07-19 Michel Schneider Ultrasound contrast agents and methods of making and using them
US20080063603A1 (en) * 1990-04-02 2008-03-13 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
US5445813A (en) 1992-11-02 1995-08-29 Bracco International B.V. Stable microbubble suspensions as enhancement agents for ultrasound echography
IN172208B (fr) * 1990-04-02 1993-05-01 Sint Sa
US6139819A (en) 1995-06-07 2000-10-31 Imarx Pharmaceutical Corp. Targeted contrast agents for diagnostic and therapeutic use
WO1998018501A2 (fr) 1996-10-28 1998-05-07 Marsden, John, Christopher Ameliorations apportees a des agents diagnostiques et/ou therapeutiques ou les concernant
GB9809084D0 (en) 1998-04-28 1998-06-24 Nycomed Imaging As Improvements in or relating to diagnostic/therapeutic agents
CA2432474C (fr) 2000-12-23 2012-06-26 Dyax Corp. Fractions de fixation de la fibrine qui conviennent comme agents d'imagerie
DK1228770T3 (da) * 2001-01-31 2005-11-07 Bracco Int Bv Törret kontrastmiddel
SI1482987T1 (sl) 2002-03-01 2014-12-31 Bracco Suisse Sa Večvalentni konstrukti za terapevtske in diagnostične aplikacije
ES2398393T3 (es) 2002-03-01 2013-03-15 Dyax Corp. Péptidos de unión a KDR y a VEGF/KDR y su uso en diagnóstico y terapia
EP1590006B1 (fr) 2003-02-04 2010-09-08 Bracco Suisse SA Agents de contraste pour ultrasons et procede pour leur elaboration
US20050025710A1 (en) 2003-07-29 2005-02-03 Michel Schneider Reconstitutable formulation and aqueous suspension of gas-filled microvesicles for diagnostic imaging
CA2547024C (fr) * 2003-12-22 2013-12-17 Bracco Research Sa Systeme de microvesicule remplie de gaz pour l'imagerie de contraste
ES2428964T3 (es) 2005-12-09 2013-11-12 Bracco Suisse Sa Conjugados de vectores específicos de una diana-fosfolípidos
EP2117603A2 (fr) * 2006-12-19 2009-11-18 Bracco International B.V. Composés de ciblage et composés thérapeutiques, et microvésicules remplies de gaz comprenant lesdits composés
US20100008978A1 (en) 2008-05-09 2010-01-14 The Regents Of The University Of California Nanoparticles effective for internalization into cells
AU2009301141B2 (en) * 2008-10-07 2015-08-27 Bracco Suisse S.A. Targeting construct comprising anti-polymer antibody and liposomes or microvesicles binding to the same
CN102614125B (zh) 2011-02-01 2018-11-02 常州长吉生物技术开发有限公司 SapC-磷脂纳米囊泡冻干制剂、其制备方法及用途
US9801959B2 (en) 2014-06-12 2017-10-31 Microvascuar Therapeutics Llc Phospholipid composition and microbubbles and emulsions formed using same
DK3233136T3 (da) 2014-12-18 2019-05-20 Bracco Suisse Sa Formulering med målrettede gasfyldte mikrovesikler
CA2989898C (fr) 2015-12-29 2024-01-16 Thermogenesis Corporation Dispositifs, systemes, et procedes de separation cellulaire
AU2017260532B2 (en) 2016-05-04 2024-08-22 Lantheus Medical Imaging, Inc. Methods and devices for preparation of ultrasound contrast agents
US9789210B1 (en) 2016-07-06 2017-10-17 Lantheus Medical Imaging, Inc. Methods for making ultrasound contrast agents
US20200360289A1 (en) * 2019-05-15 2020-11-19 Bracco Suisse Sa Freeze-dried product and gas-filled microvesicles suspension

Also Published As

Publication number Publication date
KR20220008827A (ko) 2022-01-21
AU2020276679A1 (en) 2021-11-11
ZA202108052B (en) 2022-09-28
US20220354795A1 (en) 2022-11-10
BR112021021791A2 (pt) 2021-12-21
AU2020274620A1 (en) 2021-11-11
KR20240010559A (ko) 2024-01-23
CN113825529A (zh) 2021-12-21
CA3137088C (fr) 2023-04-04
ES2965028T3 (es) 2024-04-10
US11426352B2 (en) 2022-08-30
CA3137089A1 (fr) 2020-11-19
IL288095A (en) 2022-01-01
CA3137088A1 (fr) 2020-11-19
JP7148742B2 (ja) 2022-10-05
BR112021022185A2 (pt) 2021-12-21
KR102626600B1 (ko) 2024-01-18
EP3969065A1 (fr) 2022-03-23
JP7357078B2 (ja) 2023-10-05
US20230414517A1 (en) 2023-12-28
US20220202719A1 (en) 2022-06-30
EP3969064B1 (fr) 2023-09-06
SG11202111756UA (en) 2021-11-29
CN113825529B (zh) 2024-04-19
KR102624471B1 (ko) 2024-01-15
WO2020229642A1 (fr) 2020-11-19
IL288094A (en) 2022-01-01
JP2022527227A (ja) 2022-05-31
EP3969064A1 (fr) 2022-03-23
ZA202108096B (en) 2022-07-27
US11723869B2 (en) 2023-08-15
WO2020229643A1 (fr) 2020-11-19
KR20220008277A (ko) 2022-01-20
CN113811335A (zh) 2021-12-17
JP2022532344A (ja) 2022-07-14
SG11202111754PA (en) 2021-11-29

Similar Documents

Publication Publication Date Title
US20200360289A1 (en) Freeze-dried product and gas-filled microvesicles suspension
JP4670083B2 (ja) 超音波造影剤およびその製造方法
EP2061517B1 (fr) Microvesicules remplies de gaz contenant des lipides modifies par polymeres
US20070128117A1 (en) Ultrasound contrast agents and process for the preparation thereof
US12070512B2 (en) Targeted gas-filled microvesicles formulation
JP6313329B2 (ja) ガス封入マイクロベシクル
RU2827409C2 (ru) Лиофилизированный продукт и суспензия наполненных газом микровезикул
US20200360540A1 (en) Freeze-dried product and gas-filled microvesicles suspension
EP3990032A1 (fr) Composition lyophilisée pour la préparation de microvésicules calibrées remplies de gaz
WO2024133827A1 (fr) Microvésicules remplies de gaz avec perfluoro-oléfine

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION